Eindhoven

• SAFEST Not authorised
  2022-502059-79-00 6 Ischemic stroke or transient ischemic attack
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Unknown
  2022-502779-40-99 5 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• Perioperative versus adjuvant FOLFIRINOX for resectable pancreatic cancer: the PREOPANC-3 study Pending
  2024-510617-15-00 5 Non-metastatic resectable pancreatic cancer
• Neo-adjuvant intraperitoneal chemotherapy (irinotecan) and systemic chemotherapy (mFOLFOX4-bevacizumab) prior to CRS-HIPEC for patients with … Pending
  2024-512318-16-00 4 Patients with colorectal peritoneal metastases with a PCI-score of 1-2
• Avelumab Short Maintenance Trial Pending
  2024-512975-11-01 11 urothelial cancer
• Ultrasound-guided Radiofrequency Ablation versus radioactive Iodine as treatment for Hyperthyroidism caused by Solitary Autonomous Thyroid N … Pending
  2024-515602-34-01 11 Hyperactive thyroid nodules
• Head-to-head comparison of six different botox products voor glabellar frown wrinkles. Pending
  2024-516865-35-01 6 Glabellar frown rhytides (wrinkles).
• Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for patients with unresectable colorectal peritoneal metastases – a phase … Pending
  2024-517152-34-00 4 Irresectable peritoneal metastases of colorectal cancer
• Chemo-immunotherapy before and after surgery for peritoneal metastases of large bowel cancer. Pending
  2024-518570-13-00 10 Resectable peritoneal metastases of a colorectal origin
• Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults with Non-cystic Fibrosis Bronchiectasis (NCFB) Pending
  2024-518821-13-00 4 Non-cystic Fibrosis Bronchiectasis
• PROTECx - Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer Pending
  2025-522883-34-00 6 Metastatic cervical cancer
• Adjuvant Pembrolizumab in patients with early-stage triple negative breast cancer with residual disease after treatment with chemotherapy an … Pending
  2025-524229-41-00 5 Triple negative breast cancer
• MERCURE study: MEthotrexate in ReCurrent dVIN Pending
  2025-524373-17-00 6 dVIN caused by Lichen Sclerosus
• A study to investigate the effect of adding bleximenib to standard-of-care treatment with intensive chemotherapy in patients with a specific … Recruiting
  2025-522767-15-00 5 2026-01-27 Acute Myeloid Leukemia
• Adjuvant chemotherapy for prevention of recurrence in patients with detectable ctDNA after surgery in high-riskrectal cancer. Recruiting
  2024-517700-12-00 5 2025-12-10 Rectal cancer
• T3-4-Hypo trial Recruiting
  2024-513883-24-00 5 2025-11-02 Hypothyroidism Triiodothyronine Quality of Life Persistant complaints
• ASPIRING Recruiting
  2024-516188-10-00 6 2025-10-07 Intracerebral haemorrhage
• A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia … Recruiting
  2024-512753-24-00 5 2025-08-05 Acute Myeloid Leukemia (AML)
• A study investigating the effect of adding revumenib to treatment with venetoclax + azacitidine in patients with acute myeloid leukemia (AML … Recruiting
  2024-512733-32-00 5 2025-03-31 Acute Myeloid Leukemia (AML)
• A multi-centred, partially randomised, patient-preference trial of radical surgery versus adjuvant chemoradiotherapy after local excision fo … Recruiting
  2024-517410-15-01 5 2025-01-14 Rectal cancer
• Selective Treatment of Oral Povorcitinib in Prurigo Nodularis Study 1 (STOP-PN1) Recruiting
  2024-511879-16-00 5 2024-12-12 Prurigo Nodularis
• Clinical trial that compares MK-2870 with or without pembrolizumab to chemotherapy in people with breast cancer that cannot be surgically re … Recruiting
  2023-504918-29-00 5 2024-08-22 Hormone receptor positive breast cancer
• Evaluation of the omission of dexamethasone in premedication regimens during paclitaxel treatment Recruiting
  2023-507481-43-00 11 2024-06-25 Solid tumors
• Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting
  2022-500273-14-00 10 2023-07-17 Atherosclerotic cardiovascular disease in patients with ESKD

Showing 1–24 of 161 trials